The pharmacokinetics of cefoperazone were evaluated in 28 newborn infants who were being treated for sepsis. A dose of 50 mg/kg was administered intravenously on days 0 to 2 in all, with a second dose administered on days 5 to 7 in 14 hifants. Cerebrospinal fluid penetration was also studied in seven neonates. The mean peak concentration of cefoperazone in the serum of premature infants <33 weeks of gestational age, 159 (standard deviation, ±22) ,ug/ml, was higher than concentrations in premature infants 33 to 36 weeks of age and full-term infants (110 ± 41 and 109 ± 29 jg/ml, respectively). The mean concentrations 24 h after dosage were similar in all three groups, 13 to 17 p.g/ml. The mean serum halflives were similar in the three subgroups and ranged from 7 to 9 h. After the dose at 5 to 7 days, mean blood levels in the subgroups at 0.5 h were 149, 112, and 112 1Lg/ml; 24-h levels ranged from 9 to 12~jg/ml. The mean serum half-lives ranged from 5 to 7 h. Cerebrospinal fluid levels in patients with meningitis ranged from 2.8 to 9.5 pLg/ml and in patients without meningitis from 1 to 7 ,ug/ml. Peak blood levels were 15 to 1,000 times higher than the 90% minimal inhibitory concentration of common pathogens found in newborns. These observations support the potential efficacy of cefoperazone in treatment of infections, including meningitis, in newborn infants.
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Cefoperazone (CPZ), a recently introduced broad-spectrum cephalosporin, is active in vitro against most gram-positive organisms, including group B streptococci, and gram-negative organisms, including Pseudomonas spp. (2) (3) (4) . In adults, it has been effective in the treatment of various bacterial infections, including meningitis (2, 4) . We have studied the pharmacokinetics, safety, and cerebrospinal fluid (CSF) penetration of CPZ in term and preterm neonates as a first step toward evaluating its protection against systemic infections in that age group. and was significantly greater (P < 0.05 and P < 0.03) than in the other two groups.
MATERIALS ANM METHODS
The tj,2, Vd, and AUC did not correlate with pre-and postdose bilirubin or creatinine concentrations on days 1 and 2. However, at days 5 to 7, the tj,2 (m = 80; b = 581; r = 0.6500; P < 0.02) and AUC (m = 76; b = 612; r = 0.6364; P < 0.02) were related, and Vd was inversely related (m = 0.014; b = 12.53; r = 0.6338; P < 0.02) to bilirubin levels. The concentrations of CPZ in the CSF of seven infants are presented in Table 3 . Four patients with meningitis had CPZ concentrations that ranged from 2.8 to 9.5 ,ug/ml and CSF to serum ratios that ranged from 4.2 to 31.7%. In two of three infants without meningitis, CSF levels were 1.14 and 7 ,ug/ml, with CSF to serum ratios of 0.4 and 9.2%, respectively. The remaining patient had a CSF concentration of <1 pLg/ ml.
All infants tolerated the single dose of CPZ well. None developed adverse side effects. Laboratory tests repeated after CPZ administration did not vary from pre-CPZ values. Two patients with meningitis who were severely ill before CPZ administration died of meningitis.
DISCUSSION
Our study shows that a single dose of CPZ administered during the first week of life produced high serum levels for 24 h after the dose. Although the peak levels achieved were similar to those in adults, there was a three-fold prolongation of the tj/2 and a two-fold increase in the AUC in the newborns (1, 6) . During the first days of life, renal excretion of CPZ was greater in the newborns than in adults (1, 6) , and its effect persisted for 7 days in the premature infants of <32 weeks gestation.
The higher serum levels and prolonged tj,2 in newborns may result from their relatively poor renal function and immaturity of hepatic func- days also suggests that the state of hepatic maturity is important in the pharmacokinetics of this drug.
In the neonates studied, the mean peak level of CPZ at 0.5 h was 15 to 100 times the concentration required to inhibit 90%o of common pathogens, including Escherichia coli, Proteus mirabilis, and Staphylococcus aureus (3) . Levels at 24 h were two times the concentration required to inhibit 90% of these organisms. Against group B streptococcus, a leading cause of neonatal sepsis and meningitis, levels at 0.5 and 24 h were 1,000 and 100 times greater than that needed to inhibit 100% of strains (3). Likewise, CSF levels in the three patients with meningitis caused by group B streptococcus were between 224 and 720 times higher than the concentration, <0.125 p.g/ml, required to inhibit 100%o of strains. The CSF concentration in two of three patients without meningitis was 9 to 500 times the concentration required to inhibit 100% of group B streptococcus organisms.
These findings suggest that CPZ has'potential for the treatment of meningitis in this age group. This potential assumes greater significance in view of the relative inability of other newly developed cephalosporins to cross the bloodbrain barrier (5-7). These observations support the use of cefoperazone against infections in premature and full-term neonates.
